Unicycive Therapeutics Inc (NASDAQ:UNCY) does about 366.41K shares in volume on a normal day but saw 1352281 shares change hands in the recent trading day. The company now has a market cap of 88.61M USD. Its current market price is $6.94, marking a decrease of -2.39% compared to the previous close of $7.11. The 52 week high reached by this stock is $11.00 whilst the lowest price level in 52 weeks is $2.02.
The consensus objective for the share price is $63.12, suggesting that the stock has a potential upside of 89.01% over the period.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 21, 2025 when Guggenheim initiated the stock to “Buy” and issued a price target of $6.
The current price level is 1.85%, 9.16%, and 20.51% away from its SMA20, SMA50, and SMA200 respectively, with the UNCY price moving below the 50-day SMA on current market day. Unicycive Therapeutics Inc (UNCY) stock is down -7.99% over the week and 26.39% over the past month. Its price is 10.16% year-to-date and -12.62% over the past year.
To reach the target analysts have set, the stock logically needs to grow 89.01 percent from here.
Outstanding shares total 11.97M with insiders holding 4.93% of the shares and institutional holders owning 49.60% of the company’s common stock. The company has a return on investment of -195.79% and return on equity of -2355.27%. The forward price to earnings ratio is 0.43. The beta has a value of 2.02. Price to book ratio is 7.37.
